Abstract
Treating hepatitis C virus (HCV) in pregnancy would address HCV during pre-natal care and potentially reduce the risk of vertical transmission. Response-guided therapy could provide a means to individualize and reduce duration of HCV treatment during pregnancy. Data from a 27-year-old woman indicated that
pre-treatment HCV was stable and dropped in a biphasic manner during sofosbuvir/velpatasvir therapy, reaching target not detected at time of delivery – 16 days post-initiation of therapy. Mathematical modeling of measured HCV at days 0, 7, and 14 predicted that cure could have been achieved after 7 weeks of sofosbuvir/velpatasvir, reducing duration of therapy by 5 weeks.